Studies to examine the best tumor reduction rate for predicting the pCR after two cycles docetaxel chemotherapy breast preoperative

Studies to examine the best tumor reduction rate for predicting the pCR after two cycles docetaxel chemotherapy breast preoperative - Studies to examine the best tumor reduction rate for predicting the pCR after two cycles docetaxel chemotherapy breast preoperative

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015224

Enrollment

Registered

2014-10-01

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive breast cancer

Interventions

And chemotherapy two cycles enforcement preoperative, performing a therapeutic effect judgment. If the disease has progressed obviously, to stop the treatment.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.It is diagnosed with invasive breast cancer histologically, female patients T1c-T3 without the entire treatment, N0-2.of M0. 2.Over 20 years old,71years old 3.HER2 positive breast cancer and/or triple negative breast cancer 4.ECOG performance status(PS)0-1 5.Patient consent was obtained in writing for participation in this study from the subject herself.

Exclusion criteria

Exclusion criteria: 1. Patient with suspected infection has a fever or a patient, has been complicated by infection. 2. Patients with drug allergies severe. 3. Renal failure severe, patients with (jaundice) liver failure. 4. Patients with pulmonary fibrosis or interstitial pneumonia evident in chest X-ray. 5. Enhanced MRI of patients contraindicated 6. Patients with hypertension, diabetes uncontrolled.

Design outcomes

Primary

Measure	Time frame
Cut-off value of tumor reduction rate by US evaluation for pCR prediction of chemotherapy breast cancer preoperative.	—

Secondary

Measure	Time frame
-Pathological response caliper, MMG, a contrast MRI, by needle biopsy, Ki67,optimal modalities US for predicting the pCR of breast cancer chemotherapy before surgery. -Treatment discontinuation rate due to evaluation after 2 cycles. -Safety	—

Countries

Japan

Contacts

Public ContactSayaka KUba

Nagasaki University Hospital Depertment of SURGERY

skuba@nagasaki-u.ac.jp095-819-7316

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026